Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening

Vaccine

Volumn 30, Issue 10, 2012, Pages 1813-1822

  Coupé, Veerle M H ^a   Bogaards, Johannes A ^a,b   Meijer, Chris J L M ^a   Berkhof, Johannes ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cervical cancer screening; Cost effectiveness; HPV vaccination; Simulation model

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER CYTODIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DNA SCREENING; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-BENEFIT ANALYSIS; CROSS PROTECTION; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84857452617     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.001     Document Type: Article

References (38)

1. Franco E.L., Duarte-Franco E., Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001, 164(April (7)):1017-1025.
2. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(April (9518)):1247-1255.
3. The Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(May (19)):1915-1927.
4. Adams M., Jasani B., Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007, 25(April (16)):3007-3013.
5. Franco E.L., Cuzick J., Hildesheim A., de Sanjosé S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006, 24(August (Suppl. 3)):S171-S177. [chapter 20].
6. Ginsberg G.M., Edejer T.T., Lauer J.A., Sepulveda C. Screening, prevention and treatment of cervical cancer-a global and regional generalized cost-effectiveness analysis. Vaccine 2009, 27(October (43)):6060-6079.
7. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96(April (8)):604-615.
8. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., Kuntz K.M., Goldie S.J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008, 100(March (5)):308-320.
9. Kulasingam S.L., Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290(August (6)):781-789.
10. Kulasingam S.L., Benard S., Barnabas R.V., Largeron N., Myers E.R. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008, 6(February):4.
11. Rogoza R.M., Ferko N., Bentley J., Meijer C.J., Berkhof J., Wang K.L., et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 2008, 26(September (Suppl. 5)):F46-F58.
12. Coupe V.M., de Melker H.E., Snijders P.J., Meijer C.J., Berkhof J. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Vaccine 2009, 27(August (37)):5111-5119.
13. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199(April (7)):926-935.
14. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009, 199(April (7)):919-922.
15. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(July (9686)):301-314.
16. Bosch F.X. Broad-spectrum human papillomavirus vaccines: new horizons but one step at a time. J Natl Cancer Inst 2009, 101(June (11)):771-773.
17. Liaw K.L., Hildesheim A., Burk R.D., Gravitt P., Wacholder S., Manos M.M., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001, 183(January (1)):8-15.
18. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369(June (9576)):1861-1868.
19. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(May (19)):1928-1943.
20. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(June (9580)):2161-2170.
21. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95(December (11)):1459-1466.
22. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(August (3)):621-632.
23. Bulk S., van Kemenade F.J., Rozendaal L., Meijer C.J. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004, 57(April (4)):388-393.
24. WHO guide for standardization of economic evaluations of immunization programmes 2008, World Health Organization, Geneva, [Ref type: generic].
25. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford.
26. Bogaards J.A., Coupé V.M., Meijer C.J., Berkhof J. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine 2011, 29(November (48)):8929-8936.
27. Berkhof J., Coupé V.M., Bogaards J.A., van Kemenade F.J., Helmerhorst T.J., Snijders P.J., et al. The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer 2010, 127(November (9)):2147-2158.
28. Bauch C.T., Li M., Chapman G., Galvani A.P. Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?. Lancet Infect Dis 2010, 10(February (2)):133-137.
29. Parikh S., Brennan P., Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 2003, 105(July (5)):687-691.
30. Segnan S. Socioeconomic status and cancer screening. IARC Sci Publ 1997, 138:369-376.
31. Eaker S., Adami H.O., Sparen P. Reasons women do not attend screening for cervical cancer: a population-based study in Sweden. Prev Med 2001, 32(June):482-491.
32. Hansen B.T., Hukkelberg S.S., Haldorsen T., Eriksen T., Skare G.B., Nygård M. Factors associated with non-attendance, opportunistic attendance and reminded attendance to cervical screening in an organized screening program: a cross-sectional study of 12,058 Norwegian women. BMC Public Health 2011, 11(April 26):264.
33. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370(November (9601)):1764-1772.
34. Coupe V.M., Berkhof J., Bulkmans N.W., Snijders P.J., Meijer C.J. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008, 98(February (3)):646-651.
35. Campos N.G., Rodriguez A.C., Castle P.E., Herrero R., Hildesheim A., Katki H., et al. Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study. J Infect Dis 2011, 203(March (6)):823-827.
36. Chaturvedi A.K., Katki H.A., Hildesheim A., Rodríguez A.C., Quint W., Schiffman M., et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis 2011, 203(April (7)):910-920.
37. Plummer M., Vaccarella S., Franceschi S. Multiple human papillomavirus infections: the exception or the rule?. J Infect Dis 2011, 203(April (7)):891-893.
38. Vaccarella S., Franceschi S., Snijders P.J., Herrero R., Meijer C.J., Plummer M. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2010, 19:503-510.